CureVac BV reports Q3 results
- CureVac BV press release (NASDAQ:CVAC): Q3 Pre-tax loss was €47.7M
- Revenue of €11.2M (-61.8% Y/Y).
- Cash and cash equivalents position of €540.9 million as of September 30, 2022; driven mainly by proceeds related to transfer of production capacity to GSK